Difference between revisions of "T-cell prolymphocytic leukemia"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' |- |s...") |
|||
| Line 18: | Line 18: | ||
==TPLL-ISG== | ==TPLL-ISG== | ||
*'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia] | *'''2019:''' Staber et al. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2019000402 Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia] | ||
| + | |||
| + | =All lines of therapy= | ||
| + | ==Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:893a|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 50%; text-align:center;" | ||
| + | !style="width: 25%"|Study | ||
| + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | |- | ||
| + | |[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 Dearden et al. 2001] | ||
| + | |style="background-color:#91cf61"|Non-randomized | ||
| + | |- | ||
| + | |[https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 Dearden et al. 2011] | ||
| + | |style="background-color:#91cf61"|Non-randomized | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | *[[Alemtuzumab (Campath)]] | ||
| + | |||
| + | ===References=== | ||
| + | # Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.v98.6.1721 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11535503 PubMed] | ||
| + | # Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. [https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2011-08-372854 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21948296 PubMed] | ||
[[Category:T-cell prolymphocytic leukemia regimens]] | [[Category:T-cell prolymphocytic leukemia regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:T-cell leukemias]] | [[Category:T-cell leukemias]] | ||
Revision as of 20:56, 16 December 2019
| Section editor | |
|---|---|
 |
Bhagirathbhai Dholaria, MBBS Vanderbilt University Nashville, TN |
5 regimens on this page
5 variants on this page
|
Guidelines
NCCN
TPLL-ISG
- 2019: Staber et al. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
All lines of therapy
Alemtuzumab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Dearden et al. 2001 | Non-randomized |
| Dearden et al. 2011 | Non-randomized |
Chemotherapy
References
- Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001 Sep 15;98(6):1721-6. link to original article PubMed
- Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Matutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011 Nov 24;118(22):5799-802. Epub 2011 Sep 26. link to original article PubMed